Notes

The outcome associated with impulsive indicate compare upon tunneled dialysis catheter patency.
The strong inverse correlation between FasL and TILs presence showed some insight about the interactions between cancer cells and its surroundings inside of the cervical cancer tissue. This might also be further developed to tailor a prognostic marker that can predict the outcome of therapy in patients, not only in cervical cancer, but generally in all cancer.OBJECTIVE To evaluate the response rate of Cisplatin plus Docetaxel in the treatment of locally advanced head and neck squamous cell carcinomas (HNSCC) at a tertiary care hospital in Karachi, Pakistan. MATERIALS AND METHODS It was a longitudinal study, conducted at the Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan from December 2018 to June 2019. One hundred patients of age 14-66 years of age of either gender with histologically proven Squamous Cell Carcinoma of Head and Neck, Stage III and IV (locally advanced) with no distant metastases were included in the study. Patients who were declared unresectable by the otolaryngologist and those with delayed appointment for radiation were given 3 cycles of Induction Chemotherapy with Cisplatin and Docetaxel, both at a dose of 75mg/m2 3 weekly. After 3 cycles, CT scan was repeated to assess the clinical response. Those patients who had partial or complete response as per RECIST criteria were re-assessed by the otolaryngologist and were planned for surgery if disease became resectable while other patients were referred for Concurrent Chemo-Radiation Therapy (CCRT). SPSS version 23 was used to analyze data. RESULTS The partial response was achieved in majority of the patients after Induction Chemotherapy with Docetaxel and Cisplatin (62%) with a complete response in 12 %. However, 22% showed progression of the disease, and 4% showed stable disease. The most frequent side effects observed were diarrhea (62%) and neutropenia (57%). CONCLUSION Induction chemotherapy with Cisplatin and Docetaxel is a promising regimen with good response and favorable toxicity profile and can be considered as a potentially effective outpatient regimen for locally advanced squamous cell carcinoma of head and neck.INTRODUCTION Smokeless Tobacco Products (STPs) vary significantly in their carcinogenicity, a feature accredited to the variation in the concentrations of carcinogenic chemicals. Tobacco associated bacteria are known to produce Tobacco-specific N-nitrosamines (TSNAs) and hence are determinants of TSNA levels in Tobacco. The primary objective of this study was to conduct a microbiological survey of STPs and to provide a baseline information of the bacterial communities present in the STPs. MATERIALS AND METHODS The present study analyzed the constituency of microbial communities in 7 different smokeless Tobacco products including four chewable (T1_CW to T4_CW), two snus (T5_Snus and T6_Snus) and one snuff sample (T7_Snuff) using high-throughput sequencing of the 16S rRNA based next generation sequencing. The Tobacco samples were also analyzed for pH and moisture content. Statistical analysis of the data obtained was done using SPSS software version 20. Pearson's Correlation was done to analyze the correlation m 5.62 to 6.09. CONCLUSION The current study demonstrates that ST products differ qualitatively, quantitatively, and in their bacterial composition. There is a possibility that some of these species may contribute to oral carcinogenesis, either by influencing levels of TSNAs or directly inducing chronic inflammation.INTRODUCTION Association of diabetes mellitus (DM) with head and neck cancers (HNC) is still controversial. In some studies, diabetic patients had an increased risk of cancer at some HNC subsites like oral cancer, while in other studies this risk was decreased. So, the present study aims to evaluate the association of diabetes mellitus, oral cancer with and without metformin and the role of habits in association with DM and metformin in the etiology of oral cancer. Navitoclax MATERIALS AND METHODS This study was undertaken in the Kamineni Institute of Dental Sciences in collaboration with MNJ Institute of Oncology and Regional Cancer Centre, Hyderabad. The study includes 2 main groups, they are 500 Oral cancer patients and Control group includes 500 age and gender-matched patients with habits without any oral precancerous lesion/conditions. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using unconditional logistic regression. RESULTS Out of 1000 subjects inverse relation of DM with oral cancer was observed. On comparison between oral cancer, diabetes and habits in study group and control group, decreased risk was observed with smokers (OR 1.131and 95%CI 0.68 -1.86) and non-chewers (OR 2.43 and 95% CI 1.31 - 4.49) and non-alcoholics (OR 1.78 and 95% C.I1.18 - 2.68). Metformin use among diabetic participants was associated with a decreased risk of oral cancer (OR 0.51 and 95% C.I 0.33 - 0.77). A negative association was observed in smokers (OR 0.19 and 95% C.I. 0.078 - 0.459), non-chewers (OR 0.24 and 95% C.I 0.11- 0.53) and non-alcoholics (OR 0.46 and 95% C.I. 0.29 - 0.727). CONCLUSION Thus the present population based study results suggest an inverse association of DM and oral cancer with metformin and negative association of habits with DM and Metformin in etiology of oral cancer.PURPOSE The aim of this prospective randomized study is to compare cisplatin at 2 dose levels given concurrently with intensity modulated radiation therapy (IMRT) in the treatment of locally advanced HNSCC. The main objectives were to evaluate treatment toxicities, loco-regional control, tumor response and patients compliance. METHODS Patients were randomized into two groups that either received 30 mg/m2 cisplatin weekly (arm A) or 100 mg/m2 once every 3 weeks (arm B). Radiotherapy prescribed dose was 70Gy in 33 fractions. Treatment adverse events were documented. RESULTS Sixty patients with locally advanced HNSCC were included in this study. Recruitment started at the beginning of July 2016 and ended in July 2019. The Median follow-up was 24 months. Acute non-hematological toxicities of grade 3 or higher during the treatment course were significantly more observed in Arm B patients (76.6%) compared to Arm A patients (56.6%) with a P-value of 0.007. Hematological toxicities in the form of anemia, leucopenia and neutropenia were also significantly higher in Arm B patients with a p-value of 0.
Here's my website: https://www.selleckchem.com/products/ABT-263.html